Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

VITALITY PAIN MANAGEMENT LLC

NPI: 1740033539 · LOUISVILLE, KY 40220 · Certified Registered Nurse Anesthetist · NPI assigned 04/10/2024

$156K
Total Medicaid Paid
1,493
Total Claims
1,423
Beneficiaries
2
Codes Billed
2024-07
First Month
2024-12
Last Month

Provider Details

Authorized OfficialBOSOMWORTH II, DAVID (OWNER)
NPI Enumeration Date04/10/2024

Related Entities

Other providers sharing the same authorized official: BOSOMWORTH II, DAVID

ProviderCityStateTotal Paid
VITALITY PAIN MANAGEMENT LLC LEXINGTON KY $206K
VITALITY PAIN MANAGEMENT LLC EVANSVILLE IN $7K

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2024 1,493 $156K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 1,184 1,126 $143K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 309 297 $13K